Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | STAT3 | P40763 | 15/20 | 0.48 |
| ▸ | JUN | P05412 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gaertneroside SCHEMBL420081 | 0.89 | POLB (0.60) | POLBCTDSP1MEN1MAPTKMT2A | |
| Gaertneroside SCHEMBL31179982 | 0.89 | POLB (0.60) | POLBCTDSP1MEN1MAPTKMT2A | |
| SCHEMBL29425686 | 0.88 | POLB (0.68) | POLBCTDSP1MEN1MAPTKMT2A | |
| Methoxygaertneroside SCHEMBL29425771 | 0.86 | POLB (0.56) | POLBCTDSP1MEN1MAPTKMT2A | |
| Methoxygaertneroside SCHEMBL29425775 | 0.86 | POLB (0.56) | POLBCTDSP1MEN1MAPTKMT2A | |
| Dehydrogaertneroside SCHEMBL29425897 | 0.83 | POLB (0.62) | POLBCTDSP1MEN1MAPTKMT2A | |
| SCHEMBL31239200 | 0.83 | POLB (0.52) | POLBCTDSP1MEN1MAPTKMT2A | |
| SCHEMBL31045481 | 0.83 | POLB (0.52) | POLBCTDSP1MEN1MAPTKMT2A | |
| Gaertneric Acid SCHEMBL29426009 | 0.81 | POLB (0.49) | POLBCTDSP1MEN1MAPTKMT2A | |
| SCHEMBL30833264 | 0.81 | POLB (0.51) | POLBCTDSP1MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050222053-A1 | Iridoid-saccharide compound and method of using same | HEALTH RESEARCH, INC. (US) | 2005-10-06 | — | — | US | claimed |
| EP-1527783-A1 | Iridoid-saccharide compound and method of using same | HEALTH RESEARCH, INC. (US) | 2005-05-04 | — | — | EP | claimed |
| US-20250031732-A1 | FLAVOURING AGENT, COMPOSITION, PRODUCTION METHOD AND USE OF AROMATISING AND FLAVOURING AGENTS BASED ON VANILLA EXTRACT | UNIV FEDERAL DO ESTADO DO RIO DE JANEIRO (BR) | 2025-01-30 | — | — | US | disclosed |
| CN-119039369-A | Preparation method of control of plumeria rubra glycoside | 上海诗丹德标准技术服务有限公司 | 2024-11-29 | — | — | CN | disclosed |
| CN-118271377-A | Separation method of iridoid compounds in allamanda cathayensis and application of iridoid compounds in control of pepper blast | 中国热带农业科学院香料饮料研究所 | 2024-07-02 | — | — | CN | disclosed |
| CN-118252838-A | Application of plumerianin in preparing medicine for treating or relieving fatty liver | 中国科学院上海药物研究所 | 2024-06-28 | — | — | CN | disclosed |
| WO-2023092212-A1 | FLAVOURING AGENT, COMPOSITION, PRODUCTION METHOD AND USE OF AROMATISING AND FLAVOURING AGENTS BASED ON VANILLA EXTRACTS | UNIVERSIDADE FEDERAL DO ESTADO DO RIO DE JANEIRO (BR) | 2023-06-01 | — | — | WO | disclosed |
| CN-116004326-A | Infant washing powder and preparation method thereof | 家宝生物科技香港有限公司 | 2023-04-25 | — | — | CN | disclosed |
| CN-109568332-A | Iridoid is preparing the application in analgesic | 上海交通大学 | 2019-04-05 | — | — | CN | disclosed |
| CN-108935806-A | A kind of health care tea process | 广东省生物工程研究所（广州甘蔗糖业研究所） | 2018-12-07 | — | — | CN | disclosed |
| CN-106290686-B | The method that HPLC-MS-MS measures WANGLAOJI LIANGCHA component content | 广州王老吉药业股份有限公司 | 2018-08-10 | — | — | CN | disclosed |
| CN-101669526-A | Allamanda cathartica extract and application thereof in preparing pesticide | ENVIRONMENT AND PLANT PROT INS | 2010-03-17 | — | — | CN | disclosed |
| CN-101422419-A | Toilet water and manufacture method thereof | MASSON GROUP CO LTD (CN) | 2009-05-06 | — | — | CN | disclosed |
| CN-101254185-A | Application of iridoid compound in preparing medicine for promoting nerve cell proliferation and differentiation | XUANWU HOSPITAL OF CAPITAL UNI (CN) | 2008-09-03 | — | — | CN | disclosed |
| US-20080032939-A1 | Iridoid-saccharide compound and method of using same | HEALTH RESEARCH, INC. (US) | 2008-02-07 | — | — | US | disclosed |
| US-20060216251-A1 | Topical formulations and methods of use | TRACIE MARTYN INTERNATIONAL, LLC (US) | 2006-09-28 | — | — | US | disclosed |
| US-20050222053-A1 | Iridoid-saccharide compound and method of using same | HEALTH RESEARCH, INC. (US) | 2005-10-06 | — | — | US | disclosed |
| EP-1527783-A1 | Iridoid-saccharide compound and method of using same | HEALTH RESEARCH, INC. (US) | 2005-05-04 | — | — | EP | disclosed |
| WO-1996010408-A1 | CARDIOACTIVE COMPOUNDS ISOLATED FROM WOODY PERENNIALS | THE EXECUTIVE DIRECTOR OF THE WESTERN AUSTRALIAN DEPARTMENT OF CONSERVATION AND LAND MANAGEMENT (AU) | 1996-04-11 | — | — | WO | disclosed |
| US-4410710-A | Conversion of iridoids to prostaglandins | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 1983-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060216251-A1 | Topical formulations and methods of use | CPT1B, SLC25A20, CPT1A | POLB 1930/4885CTDSP1 1521/4885MEN1 2963/4885 |
| US-20050222053-A1 | Iridoid-saccharide compound and method of using same | MKI67, SORD, DPYD | POLB 1164/4885CTDSP1 2821/4885MEN1 3990/4885 |
| US-20080032939-A1 | Iridoid-saccharide compound and method of using same | MKI67, SORD, DPYD | POLB 1164/4885CTDSP1 2821/4885MEN1 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.